{
  "url": "https://struct.news/briefs/personalis-has-one-counterparty-in-three-different-jobs",
  "title": "Personalis Has One Counterparty in Three Different Jobs",
  "summary": "Natera is disclosed as a Personalis customer, partner, and competitor. Illumina is its sole sequencing supplier, adding a second tightly defined link.",
  "published_at": "2026-08-25T23:47:38.478933+00:00",
  "publisher": "Struct",
  "usage": "Figures are as reported by the company. Quote with attribution to the source filing.",
  "company": {
    "name": "Personalis, Inc.",
    "ticker": "PSNL",
    "cik": null,
    "sector": "Healthcare",
    "industry": null
  },
  "source_filing": null,
  "comparison_filing": null,
  "reported_figures": [
    {
      "group": "Personalis’ disclosed relationship map",
      "label": "ILMN",
      "value": "ILMN",
      "display": "ILMN",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-25"
      }
    },
    {
      "group": "Personalis’ disclosed relationship map",
      "label": "NTRA",
      "value": "NTRA",
      "display": "NTRA",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-25"
      }
    },
    {
      "group": "Personalis’ disclosed relationship map",
      "label": "MRNA",
      "value": "MRNA",
      "display": "MRNA",
      "unit": "ticker",
      "period": null,
      "detail": "25.0% revenue",
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-25"
      }
    },
    {
      "group": "Personalis’ disclosed relationship map",
      "label": "TEM",
      "value": "TEM",
      "display": "TEM",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-25"
      }
    },
    {
      "group": "Personalis’ disclosed relationship map",
      "label": "NTRA",
      "value": "NTRA",
      "display": "NTRA",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-25"
      }
    },
    {
      "group": "Personalis’ disclosed relationship map",
      "label": "MRK",
      "value": "MRK",
      "display": "MRK",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-25"
      }
    },
    {
      "group": "Personalis’ disclosed relationship map",
      "label": "CAI",
      "value": "CAI",
      "display": "CAI",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-25"
      }
    },
    {
      "group": "Personalis’ disclosed relationship map",
      "label": "NTRA",
      "value": "NTRA",
      "display": "NTRA",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-25"
      }
    }
  ],
  "watch_next": [
    {
      "type": "demand",
      "statement": "Caris said higher clinical case volume, reimbursement, and average selling prices from enhanced contracting drove revenue growth.",
      "importance": "medium",
      "evidence": "The increase was driven primarily by higher clinical case volume and higher reimbursement, including improved average selling prices resulting from enhanced contracting.",
      "source_date": "2026-08-05"
    },
    {
      "type": "partner_dependency",
      "statement": "Filing attributes approximately 9% of DIS volume growth to new Corewell relationship and increased testing at Fresenius Medical Care dialysis clinics.",
      "importance": "high",
      "evidence": "DIS volume increased by 13.1% compared to the prior year period principally driven by organic growth of 13.0%, of which approximately 9% was due to both our new relationship with Corewell Health to provide Collaborative Lab Solutions and increasing our laboratory testing at dialysis clinics owned by Fresenius Medical Care in the United States.",
      "source_date": "2026-07-23"
    },
    {
      "type": "input_costs",
      "statement": "Reported YoY increase in cost of product revenues of ~$60.6M (32.8%), with component rises in inventory, labor, third-party fees and depreciation.",
      "importance": "medium",
      "evidence": "During the three months ended March 31, 2026, cost of product revenues increased compared to the three months ended March 31, 2025 by approximately $60.6 million, or 32.8%, primarily due to higher costs related to inventory consumption of $21.9 million driven by an increase in accessioned cases, a $17.7 million increase in labor costs, a $13.3 million increase in third-party fees, and a $7.7 million increase in equipment and related depreciation expense, labor, overhead, shipping and other relat",
      "source_date": "2026-05-08"
    },
    {
      "type": "demand",
      "statement": "Testing revenue grew 26% year-over-year, driven primarily by a 19% volume increase along with improved average selling price and collections.",
      "importance": "medium",
      "evidence": "The 26% growth in testing revenue was primarily driven by a 19% volume increase, as well as improved ASP and prior period collections.",
      "source_date": "2026-05-06"
    }
  ],
  "related_tickers": [
    "CAI",
    "DGX",
    "GH",
    "GRAL",
    "ILMN",
    "MRK",
    "MRNA",
    "MYGN",
    "NTRA",
    "PSNL",
    "TEM",
    "VCYT"
  ],
  "disclaimer": "Descriptive reporting of filed results. Not investment advice, and contains no forecast or recommendation."
}